OCUGEN, INC. Accrued Liabilities and Other Liabilities
OCUGEN, INC. (OCGN) had Accrued Liabilities and Other Liabilities of $11.01 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedLiabilitiesAndOtherLiabilities · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities and Other Liabilities $11.01M.
- 2026-03-31: Accrued Liabilities and Other Liabilities $11.61M.
- 2025-12-31: Accrued Liabilities and Other Liabilities $14.73M.
- 2025-09-30: Accrued Liabilities and Other Liabilities $14.93M.
| Period end | Accrued Liabilities and Other Liabilities | Accrued Liabilities and Other Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $11.01M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $11.61M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $14.73M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $14.93M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $12.90M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $12.93M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $15.50M 10-K · filed 2026-03-04 | |
| 2024-09-30 | $12.47M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $12.81M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $12.43M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $13.34M 10-K · filed 2025-03-05 | |
| 2022-12-31 | $19.97M 10-K · filed 2024-04-16 | $9.90M 10-K · filed 2023-02-28 |
| 2021-12-31 | $4.33M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $3.96M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $3.87M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $2.70M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $2.94M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |